Literature DB >> 7911328

Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro.

C C Rider1, D R Coombe, H A Harrop, E F Hounsell, C Bauer, J Feeney, B Mulloy, N Mahmood, A Hay, C R Parish.   

Abstract

Chemically modified heparins were tested for their activities in (i) inhibiting HIV-1 replication in vitro and (ii) inhibiting the binding to recombinant HIV-1 gp120 of monoclonal antibodies specific for the V3 loop. The results reveal that N-desulfation reduces activity, although this is largely restored on N-acetylation. Selective O-desulfation also markedly reduces activity, whereas carboxyl reduction has little effect. Overall these results show that the anti-HIV-1 activity of heparin does not depend simply on negative density, and indicate instead that particular structures, notably O-sulfates, are involved. Our studies reveal that for chemically modified heparins and heparin-derived fragments there is a striking correlation between anti-HIV-1 activity in vitro and binding to the V3 loop of gp120 in solid phase ELISA. This strongly suggests that the heparin exerts its anti-HIV-1 activity by binding to the V3 loop of gp120.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911328     DOI: 10.1021/bi00188a029

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

Review 1.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

Review 2.  Glycobiology and medicine: an introduction.

Authors:  J Axford
Journal:  J R Soc Med       Date:  1997-05       Impact factor: 5.344

3.  Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.

Authors:  M Moulard; H Lortat-Jacob; I Mondor; G Roca; R Wyatt; J Sodroski; L Zhao; W Olson; P D Kwong; Q J Sattentau
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 4.  The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection.

Authors:  C C Rider
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

5.  Binding of recombinant feline immunodeficiency virus surface glycoprotein to feline cells: role of CXCR4, cell-surface heparans, and an unidentified non-CXCR4 receptor.

Authors:  A de Parseval; J H Elder
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists.

Authors:  Antonella Bugatti; Cinzia Giagulli; Chiara Urbinati; Francesca Caccuri; Paola Chiodelli; Pasqua Oreste; Simona Fiorentini; Alessandro Orro; Luciano Milanesi; Pasqualina D'Ursi; Arnaldo Caruso; Marco Rusnati
Journal:  J Biol Chem       Date:  2012-11-19       Impact factor: 5.157

Review 7.  High-field NMR as a technique for the determination of polysaccharide structures.

Authors:  B Mulloy
Journal:  Mol Biotechnol       Date:  1996-12       Impact factor: 2.695

8.  Glycoside analogs of beta-galactosylceramide, a novel class of small molecule antiviral agents that inhibit HIV-1 entry.

Authors:  Himanshu Garg; Nicholas Francella; Kurissery A Tony; Line A Augustine; Joseph J Barchi; Jacques Fantini; Anu Puri; David R Mootoo; Robert Blumenthal
Journal:  Antiviral Res       Date:  2008-05-19       Impact factor: 5.970

9.  Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer.

Authors:  Natalia Teleshova; Theresa Chang; Albert Profy; Mary E Klotman
Journal:  Antimicrob Agents Chemother       Date:  2008-03-10       Impact factor: 5.191

10.  A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry.

Authors:  Françoise Baleux; Latino Loureiro-Morais; Yael Hersant; Pascal Clayette; Fernando Arenzana-Seisdedos; David Bonnaffé; Hugues Lortat-Jacob
Journal:  Nat Chem Biol       Date:  2009-09-06       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.